Recent Press Releases & News
CHRS earnings at a glance
Coherus Oncology, Inc. (CHRS) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of -$0.22, compared with -$0.38 in the same quarter last year (+42%). The options market is pricing a move of about ±45.5% after the report, a range of roughly $0.55 to $1.45 from today's $1.00. Over its last 6 reports the stock rose the next day 1 time and fell 5, moving ±10.4% on average; after the most recent report on Aug 5, 2026 it moved -12.8%. That means options currently expect more movement than CHRS has typically delivered. CHRS beat the consensus EPS estimate in 1 of its last 6 reported quarters. Implied volatility is currently 272%. The share price of $1.00 sits near its 52-week low.
Overview
Earnings trends
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | $-0.22 | $-0.16 | -37.5% | +59.0% | -12.8% | earnings |
| Mon May 11, 2026 | Mar/2026 | $-0.27 | $-0.29 | +6.9% | +34.1% | -12.3% | earnings |
| Mon Mar 9, 2026 | 8K 2026-03-09 | $-0.39 | $-0.38 | -2.6% | — | +1.0% | earnings |
| Thu Nov 6, 2025 | Sep/2025 | $-0.38 | $-0.37 | -2.7% | — | -10.1% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-0.39 | $-0.25 | -56.0% | — | -7.1% | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.41 | $-0.40 | -2.5% | — | -19.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.09 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.11 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.91 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.49 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.96 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Nov 5, 2026 | Sep/2026 | OTHER | -$0.22 | -$0.38 | +42.1% |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $12M | — | $12M | $10M | $8M | — | $6M |
| Cost of revenue | $4M | $4M | — | $4M | $3M | $3M | — | $3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-32M | $-36M | — | $-44M | $-45M | $-45M | — | $-47M |
| Net income | $-21M | $-38M | — | $-36M | $298M | $-57M | — | $-11M |
| EPS (diluted) | $-0.13 | $-0.28 | — | $-0.31 | $2.57 | $2.57 | — | $-0.09 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $83M | $115M | $89M | $103M | $217M | $82M | $126M | $98M |
| Inventory | $6M | $5M | $3M | $2M | $5M | $4M | $4M | $48M |
| Total current assets | $134M | $206M | $207M | $461M | $380M | $310M | $342M | $369M |
| Total assets | $191M | $266M | $258M | $517M | $439M | $371M | $449M | $505M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $130M | $187M | $197M | $429M | $320M | $555M | $581M | $593M |
| Total equity | $61M | $79M | $61M | $88M | $120M | $-183M | $-132M | $-88M |
Implied volatility — last 90 days
Sector peers
CHRS earnings FAQ
When is CHRS's next earnings date?
Coherus Oncology, Inc. is expected to report on November 5, 2026.
What is CHRS's expected move for earnings?
Options currently price a move of about ±45.5%, or $0.45 per share either way from $1.00.
How does CHRS stock usually react to earnings?
Across the last 6 reports the average next-day move was ±10.4%, up 1 times and down 5 times.
What EPS are analysts expecting from Coherus Oncology, Inc.?
The consensus estimate is -$0.22 per share, versus -$0.38 a year ago.
What is CHRS's implied volatility?
CHRS's at-the-money implied volatility is about 272% based on the latest options snapshot.